NLRP1 and multiple sclerosis: A small-molecule inhibitor (MCC950), specifically targeting NLRP3 inflammasome activation (ASC oligomerization) but not AIM2, NLRC4 or NLRP1 inflammasomes, was able to attenuate mouse models of multiple sclerosis (149) and Parkinson’s disease (150).